Selenium, Ltd. is a technology company specializing in the prevention of bacterial biofilm formation using molecular additives of redox active selenium for medical, dental, ophthalmic and industrial applications. Our Seldox™ technology addresses the needs of many biomedical and industrial companies for an effective, low cost, and safe antibiofilm coated or integrated technology.
Selenium Ltd.'s proprietary technology is able to inhibit bacterial biofilm formation and attachment on surfaces through a covalently linked, catalytic, and safe compound that does not leach into the surrounding environment. These properties allow for protection against biofilm for the duration of the useful life of the substrate.
Selenium compounds may be used as an arming agent for antibodies, peptides, small molecules, and nucleotides.
Selenium has an extensive intellectual property portfolio including foreign and U.S. Patents.
About Our Anti-Biofilm Technology
Based on redox chemistry, Seldox compounds create a flux of superoxide radicals. These superoxide radicals can affect biofilm growth by altering protein folding needed to initiate a biofilm, inhibiting needed respiratory and metabolic functions, causing minor membrane lesions, and even leading to the development of longer lasting radicals. This process mimics the body's own defense against bacteria. White blood cells, leukocytes, can produce superoxide radicals in order to destroy bacteria during phagocytosis.
Seldox compounds enable focused inhibition while not harming bystander cells. The half-life of the superoxide radicals limits the effective zone to approximately 350 angstroms. This short active range makes the technology ideal for the prevention of biofilm formation. In addition, natural mammalian cell defenses to oxidative stress are sufficient to deal with dilute superoxide concentrations, making it safe for medical applications.
Industry Validation and National Recognition
"Selenium received a $140,000 Small Business Technology Transfer (STTR) grant for research and development of antimicrobial dental water lines."
"Selenium, Ltd. received a National Institutes of Health (NIH) two-year $912,943 grant to develop antimicrobial dental devices and water lines."
"Selenium recieved a $500,000 Small Business Innovation Research (SBIR) grant for research and development of antimicrobial reverse osmosis spacers."